Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 561Leukemia 282Precursor Cell Lymphoblastic Leukemia-Lymphoma 235Lymphoma 160Myelodysplastic Syndromes 111Burkitt Lymphoma 91Congenital Abnormalities 86Lymphoma, Non-Hodgkin 85Leukemia, Monocytic, Acute 84Leukemia, Myelomonocytic, Acute 82Lymphoma, Large B-Cell, Diffuse 80Leukemia, Erythroblastic, Acute 75Leukemia, Megakaryoblastic, Acute 72Recurrence 70Lymphoma, Mantle-Cell 70Lymphoma, Follicular 49Hodgkin Disease 44Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Lymphoma, Large-Cell, Immunoblastic 37Blast Crisis 37Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 33Myeloproliferative Disorders 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, B-Cell, Marginal Zone 24Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Leukemia, Basophilic, Acute 22

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Monatide (IMS 3015) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Pathologic Complete Response × Cytarabine × Clear all
NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01656252 2020-11-03

PrE0901

PrECOG, LLC.

Phase 1/2 Terminated
15 enrolled 5 charts
Classical hematologyOther hematologic neoplasm

Jacobs syndrome, Pathologic Complete Response, Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01843179 2017-02-17

Sulindac for Patients With AML

Massachusetts General Hospital

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡